Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies